Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief

This article was originally published in The Rose Sheet

Executive Summary

P&G puts health care and grooming head David Taylor in charge of the firm’s global beauty business as well, positioning him as a possible successor to CEO Lafley. More news in brief.

You may also be interested in...



Diamond Wipes’ FDA Headaches Suggest Cosmetic Recall Hangover

Following an FDA warning letter in 2016 for an unapproved sunscreen drug product, Diamond Wipes now must answer agency concerns regarding “poor-quality water” used in its manufacturing operations. Both warnings stemmed from inspections in the wake of a 2014 product recall for mold contamination.

FDA Updates Its Microbiological Safety Webpage Amid Recall Flurry

Gilchrist & Soames’ recall of bath and body products due to microbial contamination marks a five-month trend in FDA’s enforcement reports. On its Microbiological Safety webpage, updated Feb. 12, FDA refers to a public meeting it held on the issue in 2011, where industry representatives warned that a shrinking preservative palette could put consumers at risk.

P&G Portfolio Trimming ‘Full Steam Ahead’ As Currency Effects Pummel Profit

P&G’s net income fell 31% in its second quarter and will decline for its full fiscal 2015 due to foreign exchange; the firm remains focused on core brand growth and innovation while it weathers the storm. So far, P&G has sold or consolidated 35 of the 90 to 100 brands on its streamlining chopping block, it says.

Related Content

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS019667

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel